Titlebook: Cancer Immunotherapies; Solid Tumors and Hem Priya Hays Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusive license

只看該作者 · 發(fā)表于 2025-3-27 00:17:23

Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution,is revolutionizing the standard of care in certain patients with genitourinary malignancies. As modest clinical benefits of IL-2 for metastatic renal cell carcinoma and Bacillus Calmette-Guerin therapy for early-stage bladder cancers in the past years, immune checkpoint inhibitors therapies demonstr

只看該作者 · 發(fā)表于 2025-3-27 05:12:18

只看該作者 · 發(fā)表于 2025-3-27 06:11:16

Chimeric Antigen Receptor Immune Cells from Human Pluripotent Stem Cells,CAR-T therapy has been challenging due to labor some manufacturing processes for every patient, and the cost due to the complexity of the process. Moreover, T cell dysfunction results from the immunosuppressive tumor microenvironment in certain patients. Considering technical challenges in autologou

只看該作者 · 發(fā)表于 2025-3-27 12:15:08

只看該作者 · 發(fā)表于 2025-3-27 17:35:06

只看該作者 · 發(fā)表于 2025-3-27 20:27:36

只看該作者 · 發(fā)表于 2025-3-27 23:12:30

只看該作者 · 發(fā)表于 2025-3-28 03:28:56

只看該作者 · 發(fā)表于 2025-3-28 10:05:48

978-3-030-96378-1The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl

只看該作者 · 發(fā)表于 2025-3-28 10:34:43

		自動登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務(wù)流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學(xué)	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點(diǎn)評	投稿經(jīng)驗(yàn)總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學(xué)	Yale Uni.	Stanford Uni.
\|Archiver\|手機(jī)版\|小黑屋\| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-23 15:01
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved